TDF + LNG Vaginal Ring

Alternative Name: Tenofovir Disoproxil Fumarate (TDF) + Levonorgestrel Vaginal Ring

Product Details

User: Female

Hormonal: Yes

Delivery Method: Vaginal Ring

Duration Type: Short-acting

Duration: 30 days

Regimen:
  • leave in place for 30 days

Active Pharmaceutical Ingredient (API):
  • levonorgestrel
  • tenofivir disoproxil fumarate (TDF)

Inactive material: polyurethane

Multipurpose Preventive Technology (MPT): Yes

Status Details

Developer: Albert Einstein College of Medicine, NIAID, Northwestern University

Project Phase: Pre-Clinical and Clinical Development

Development Stage: Phase I

Active Development: Unknown

Status Details:
  • A clinical trial conducted in 2014 in New York evaluated the ring in 60 women over 14 days. The trial assessed the ring's safety and measured how much of the drug is released and the properties of the ring after use.
  • Another phase I trial began in 2017 to evaluate the safety of the ring over 84 days. The trial was not completed.

Additional Information

References:

Vertical Tabs

Print